Do you want to read an article? Please log in or register.
Two-year outcomes of intravitreal aflibercept in a Swiss routine treat and extend regimen for patients with neovascular age-related macular degeneration
Macular Diseases
COMMENTED
Related content
Macular Diseases
Intravitreal aflibercept for neovascular age-related macular degeneration in patients aged 90 years or older: 2-year visual acuity outcomes
Eye (Lond).
Chatziralli I, Regan SO, Mohamed R, Talks J, Sivaprasad S; UK Aflibercept Users Group.
doi: 10.1038/s41433-018-0114-3.
Macular DiseasesRetinal Diseases
One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration
Br J Ophthalmol.
Braimah IZ, Agarwal K, Mansour A, Chhablani J; Ziv-aflibercept Study Group
doi: 10.1136/bjophthalmol-
Macular Diseases
EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: THE ARIES STUDY
Retina
Mitchell P, Holz FG, Hykin P, Midena E, Souied E, Allmeier H, Lambrou G, Schmelter T, Wolf S
doi: 10.1097/IAE.0000000000003128
COMMENTED
Macular Diseases
Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated With Ranibizumab Using a Treat and Extend Regimen: FLUID Study 24 Month Results
Ophthalmology.
Guymer RH, Markey CM, McAllister IL, Gillies MC, Hunyor AP, Arnold JJ; FLUID Investigators
doi: 10.1016/j.ophtha.2018.11.025.
COMMENTED
Macular Diseases
Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial
★ 3
Recommended by
Prof. Dr Daniel Barthelmes, Faculty Member
★ 3
Recommended and commented by
Prof. Dr Stephan Michels, Faculty Member
JAMA Ophthalmol.
Kertes PJ, Galic IJ, Greve M, Williams G, Baker J, Lahaie M, Sheidow T
doi: 10.1001/jamaophthalmol.2019.5540.
COMMENTED
Macular Diseases
Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial
JAMA Ophthalmol.
Gillies MC, Hunyor AP, Arnold JJ, Guymer RH, Wolf S, Ng P, Pecheur FL, McAllister IL
doi: 10.1001/jamaophthalmol.
Macular Diseases
Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies
Adv Ther.
Carrasco J, Pietsch GA, Nicolas MP, Koerber C, Bennison C, Yoon J
doi: 10.1007/s12325-019-01147-6.
Macular Diseases
Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry
Ophthalmology.
Rao P, Lum F, Wood K, Salman C, Burugapalli B, Hall R, Singh S, Parke DW 2nd2, Williams GA
doi: 10.1016/j.ophtha.2017.10.010.
COMMENTED
Macular Diseases
Aflibercept for age-related macular degeneration: 4-year outcomes of a 'treat-and-extend' regimen with exit-strategy
★ 1
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
Br J Ophthalmol
Jaggi D, Nagamany T, Ebneter A, Munk M, Wolf S, Zinkernagel M
doi: 10.1136/bjophthalmol-2020-316514